RGCC International

16/10/2026

How does support a doctor’s treatment decisions? Hear the perspective of Dr. Clifford Fetters, MD, from Health and Wellness of Carmel (US).

He shares how RGCC testing can provide additional insights into a patient's , supporting more informed and personalized treatment decisions.

12/10/2026

🎗️ October is Breast Cancer Awareness Month.

This month we join the global effort to raise awareness and support continued progress in breast cancer research.

🔬🧬 Genetic testing is the future of cancer diagnosis providing clinicians with critical insights into disease risk, and RGCC is leading the way.

ℹ️ At RGCC, we offer a range of genetic tests that empower clinicians to make data-driven decisions, supporting precision medicine oncology and fully personalized cancer care.

🔗 Learn more about and treatment options:
👉 https://rgcc-international.com/patient-information/therapy-breast-cancer/

08/10/2026

🧬 Metastasis occurs when cancer cells spread from the primary tumor to other parts of the body. According to , widespread metastases are the primary cause of death from .

🔬 RGCC’s Oncotrace test analyzes circulating cells (CTCs) from a blood sample, providing insights into cancer progression and the potential for metastatic spread.

🔗 Learn more about Oncotrace here:
👉 rgcc-international.com/tests/oncotrace/

04/10/2026

Salivary Gland Cancer Day is a global awareness day dedicated to shining a light on the many rare cancers that affect the salivary glands.

📚 According to the , there are several different salivary glands in and around the mouth, where both benign amalignant can develop. Compared to other types of head and neck cancers, salivary gland are rare.

🔗 Learn more about Salivary Gland Cancer here: www.cancer.org/cancer/types/salivary-gland-cancer.html

03/10/2026

Behind every diagnosis is an individual disease and an individual patient.

👩‍⚕ Meet Dr. Tristin Wallace, a Board-Certified, Licensed Naturopathic Doctor and trusted RGCC Certified Practitioner. She trusts RGCC testing to guide her on which natural and conventional anti-cancer protocols can be demonstrated to treat each patient's specific cancer type.

Discover more insights from both patients and healthcare professionals:
👉 rgcc-international.com/testimonials/

29/09/2026

Can a blood test predict how well a patient will respond to various conventional therapies?

CAMBISeq ( Analysis Mutational Burden Instability Sequencing) is an advanced RGCC blood test that provides next-generation sequencing (NGS) analysis of both DNA and RNA. Our scientists use the test results as biomarkers to assess their sensitivity to immunotherapy and targeted therapies.

🔗 Explore CAMBISeq today and find out if it's the right fit for your cancer care journey: rgcc-international.com/tests/cambiseq/

23/09/2026

We were proud to participate in this year's National Cancer Congress Malaysia, held in collaboration with the National Cancer Society Malaysia (NCSM), bringing together healthcare leaders, clinicians, and policymakers dedicated to improving care nationwide.

This milestone builds on our July 2026 MOU with NCSM, which aims to expand access to therapeutic sensitivity testing for eligible patients within Malaysia's public healthcare sector.

We look forward to building on this momentum with NCSM, working together to bring precision closer to cancer patients across Malaysia.

👉 Read more:

RGCC participates in the 2026 National Cancer Congress Malaysia, building on its MOU with NCSM to expand precision oncology access.

17/09/2026

🚀 Big news from our R&D lab in Halle (Saale), Germany.

Our RGCC CE R&D facility has undergone a major expansion, growing from 150 m² in 2019 to 585 m² by the end of 2025, and now to 2,070 m² this summer.

This growth was made possible through the leadership of Dr. Stefan Rubner, Head of the Laboratory, at RGCC Central Europe.

This expanded footprint gives us the foundation to grow our existing research areas and launch new ones. Here's a sneak peek of what our team is working on:

🔬 Cancer target identification & validation for drug development
🔬 Evaluation of cancer-related biomarkers
🔬 Big Data analysis of transcriptomic and proteomic datasets
🔬 3D tumor microenvironment reconstruction
🔬 Cell line development for rare cancer types
🔬 ATMP development, including gene and cellular therapies
🔬 Laboratory automation for screening approaches
🔬 Expanding collaborations through regional networks

Our team has grown to 22 employees, with more joining by the end of the year, and we're just getting started.

14/09/2026

📢 New peer-reviewed research from the team is now published in the Journal of Immunology Research.

Our scientists investigated the most widely used cell line for studying immune functionality in vitro by comparing monocytic THP-1 cells sourced from two different depositors. The researchers found significant differences between the two THP-1 clones and their further differentiated macrophage types. Many genes and proteins involved in immune functions, signaling pathways, and metabolism were expressed at different levels, highlighting the variability between THP-1 subtypes, which has direct implications for immunological research.

📖 Read the study here: rgcc-international.com/published-articles/thp-1-subtypes/

09/09/2026

What makes 's research truly unique? The ability to bring together all the disciplines needed for both basic and applied cancer research — from bioscience and chemistry to clinical collaboration — all under one roof.

From developing new technologies in the lab to working closely with clinicians who see the real-world impact on patients, our team is committed to advancing science at every level.

👉 Head to our Youtube channel to watch the full interview with Dr. Theresa Wiessner-Kroh and Dr. Stefan Rubner from RGCC's R&D facilities in Halle, Germany >> youtube.com/watch?v=MJ0cewWT_jw&t=16s